tetano
Editor, Senior Moderator
Heliyon. 2019 Feb 5;5(2):e01154. doi: 10.1016/j.heliyon.2019.e01154. eCollection 2019 Feb.
[h=1]Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection.[/h] Desheva YA[SUP]1,[/SUP][SUP]2[/SUP], Leontieva GF[SUP]1[/SUP], Kramskaya TA[SUP]1[/SUP], Landgraf GO[SUP]2[/SUP], Sychev IA[SUP]1[/SUP], Rekstin AR[SUP]1[/SUP], Suvorov AN[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.
[h=4]KEYWORDS:[/h] Immunology; Microbiology; Vaccines; Virology
PMID: 30839941 PMCID: PMC6365543 DOI: 10.1016/j.heliyon.2019.e01154
Free PMC Article
[h=1]Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection.[/h] Desheva YA[SUP]1,[/SUP][SUP]2[/SUP], Leontieva GF[SUP]1[/SUP], Kramskaya TA[SUP]1[/SUP], Landgraf GO[SUP]2[/SUP], Sychev IA[SUP]1[/SUP], Rekstin AR[SUP]1[/SUP], Suvorov AN[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.
[h=4]KEYWORDS:[/h] Immunology; Microbiology; Vaccines; Virology
PMID: 30839941 PMCID: PMC6365543 DOI: 10.1016/j.heliyon.2019.e01154
Free PMC Article